|
||||||||||||||||||||||||||||||||||||||
|
|
WCTF.org Transplant NewsTransplant news, links, and other general medical news -- updated regularly.Thursday, May 1, 2008Organ Transplants | Medical Services | UCSF Children's Hospital
transplants should not experience personality changes that parallel the personalities of donors they have never. The United Organ Transplant Association, is a nonprofit charitable [continued]
Heart Transplant and Recovery: Tranceformation Works
Tranceformation Works Heart Transplant and Recovery: Customer Rating: not yet rated Quantity in Basket: none [more]
New Infusion Suite at the Children's Hospital at Montefiore Blends Child-Friendly Design With Expert Clinical Care
New Infusion Suite at the Children's Hospital at Montefiore Blends Child-Friendly Design With Expert Clinical Care
New Outpatient Unit for Treatment of Pediatric Cancer and Blood Disorders Made Possible by $12 Million Gift from Jerome L. Greene Foundation NEW YORK, May 1 /PRNewswire-USNewswire/ -- A new outpatient infusion suite at The Children's Hospital at Montefiore (CHAM) provides a unique therapeutic environment for children facing life-threatening cancer and blood disorders by combining expert clinical care with comforting child-friendly design. (Photo: http://www.newscom.com/cgi-bin/prnh/20080501/DC21153 ) Built to accommodate the growing patient volume at the hospital's Division of Pediatric Hematology/Oncology, the new infusion unit was made possible by a $12 million gift from the Jerome L. Greene Foundation. It is the latest development within CHAM's Division of Pediatric Hematology/Oncology, which is the only center in the New York City area to offer all services under one roof that are needed for the care and treatment of pediatric cancer and blood disorders. "We are proud that our division of pediatric hematology/oncology has evolved to become a destination for young patients in need of highly specialized clinical expertise and innovative therapies," said Steven M. Safyer, MD, President and CEO, Montefiore Medical Center. "We applaud the Greene family's recognition of the division's significant growth and potential and are deeply grateful for their ongoing and generous support of our patients." Dawn M. Greene, President and CEO of the Jerome L. Greene Foundation, announced the $12 million donation last spring in honor of her late husband, Jerome L. Greene, the noted attorney, real estate investor and philanthropist who died in 1999. A longtime trustee of Montefiore Medical Center, Mr. Greene was founding chairman of the Mosholu Preservation Corporation, a non-profit organization established by Montefiore in 1981 to revitalize the community surrounding the medical center. In recent years, the Greene family has provided significant financial support to projects at Montefiore, including construction of the Jerome L. and Dawn Greene Medical Arts Pavilion at the medical center's Moses campus. "Our support of the pediatric hematology/oncology team at the Children's Hospital at Montefiore is inspired by the superior clinical care they provide, with a level of compassion that any parent would want for their child," said Dawn Greene. "The atmosphere is so important when a young person is ill, and this new infusion unit will surround children with a great deal of warmth and comfort as they complete long and difficult treatments." High-tech meets child-friendly design "A generation ago, children with cancer had limited treatment options and often poor prognoses. Today, our ability to develop and administer groundbreaking therapies is giving many children the chance to live to adulthood and far beyond," said Richard Gorlick, MD, Vice Chairman and Chief of Pediatric Hematology/Oncology, CHAM. "At The Children's Hospital at Montefiore, we have an enthusiastic team that is committed to providing the highest quality care. The Greene Foundation's gift allows us to realize our vision to create a child-friendly environment where superior clinical expertise and research will lead us to even greater advances in the treatment of pediatric cancer and blood disorders." The new, 4,800-square-foot outpatient suite houses 11 infusion bays and 5 exam rooms, with special features including plasma TVs in each bay that provide a welcome distraction as children receive chemotherapy. Designed by visionary architect David Rockwell, whose firm was responsible for designing CHAM, the unit features unique visuals, local references and touchable art such as a Periaktoi play wall, a hands-on display where children can create wall-sized images of rhinos, a parrot and a school of dolphins by rotating triangular blocks. Prehistoric and modern-day "Birds of the Bronx" fly overhead, reflecting children's connection to the universe and their roles as "explorers" on a journey to healing. Gift supports growing pediatric hematology/oncology patient population The Division of Pediatric Hematology/Oncology at CHAM addresses the complex physical, medical and emotional needs of children with cancer and blood disorders, providing specialty care including bone marrow transplantation, resources of the area's only NIH-funded Sickle Cell Center, and access to the latest national and international clinical trials through its participation in the Children's Oncology Group. In addition, researchers at CHAM are focused on developing new treatment agents and bringing them into clinical trials as quickly as possible, providing alternatives such as inhaled chemotherapy to children for whom standard interventions have failed. Complementing these services is a multi-faceted integrative medicine program that incorporates a range of healing therapies including martial arts therapy, yoga, massage and aromatherapy, holistic cooking classes and soon, acupuncture. The Greene Foundation's gift was given in support of the division's dramatic growth since Dr. Gorlick was appointed chief in 2004, and the new infusion suite is the centerpiece of the program's physical redesign. In 2007, nearly 2,500 infusions were administered in CHAM's pediatric day hospital, compared to 290 in 2004, with the program steadily receiving referrals from Westchester, Rockland and Orange counties. The completion of the new outpatient infusion suite is the first of two major phases of construction made possible by the Greene donation. Phase II will be a total renovation of the pediatric hematology/oncology inpatient unit, which is targeted for completion in the winter of 2009. The funds have also supported recruitment of pediatric hematology/oncology physician specialists and other key members of the care team including an advance practice nurse, a child life specialist and a social worker. Please visit our website, www.montekids.org, for more information about The Children's Hospital at Montefiore. First Call Analyst: Photo: http://www.newscom.com/cgi-bin/prnh/20080501/DC21153 CONTACT: Anne McDarby, amcdarby@montefiore.org, or Pamela Adkins, Web Site: ------- Thoratec Reports 12 Percent Increase in First Quarter Revenues
Thoratec Reports 12 Percent Increase in First Quarter Revenues
RECORD QUARTER DRIVEN BY 13 PERCENT INCREASE IN CARDIOVASCULAR DIVISION REVENUES PLEASANTON, Calif., May 1 /PRNewswire-FirstCall/ -- Thoratec Corporation (NASDAQ:THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, today reported record quarterly revenues of $64.4 million for the first quarter of fiscal 2008. Revenues for the quarter ended March, 29, 2008, increased 12 percent over revenues of $57.3 million in the first quarter of last year, including a 13 percent increase in revenues in the company's Cardiovascular Division. Net income on a GAAP basis in the first quarter of fiscal 2008 was $0.3 million, or $0.01 per diluted share, compared with a net loss of $0.3 million, or $0.01 per share, in the same period a year ago. Non-GAAP net income, which is described later in this press release, was $4.5 million, or $0.08 per diluted share, in the first quarter of 2008 compared with non-GAAP net income of $4.3 million, or $0.08 per diluted share, in the same period a year ago. "The increase in our Cardiovascular Division revenues was driven by continued strong HeartMate II growth in Europe, solid HeartMate performance in the U.S., particularly in our clinical trial, and continued progress with our CentriMag program," noted Gary F. Burbach, president and chief executive officer. "At the same time, our International Technidyne Corporation (ITC) division turned in solid results with an 11 percent increase in year-over-year revenues, due primarily to a strong performance in our international business. Growth at ITC was driven by sales of our ProTime system in Europe, market share gains with our Hemochron hospital point-of-care coagulation and Irma TruPoint blood gas devices in both Europe and Asia, as well as good initial traction in our partnership with IDEXX to address the U.S. veterinary market," Burbach continued. Burbach noted that on April 21, 2008, Thoratec announced approval of its PMA (PreMarket Approval) application, allowing the use of the HeartMate II as a bridge-to-transplantation (BTT) in patients suffering from advanced-stage heart failure. The HeartMate II is the first continuous flow device to receive FDA approval for this intended use in the U.S. and represents an important milestone in the treatment of advanced-stage heart failure. "As the clinical trial data indicated, we had strong results across all endpoints, including survival, adverse event rates, functional status and quality of life. We believe this approval further demonstrates our leadership position in the mechanical circulatory support arena with the industry's broadest portfolio of devices. The initial response from the clinical community since our announcement has been highly positive and we have initiated our commercial launch program to add new centers." "Helping to fuel enthusiasm for the device," Burbach continued, "has been the presentation of new data at two major medical meetings over the past few weeks. Several of these presentations involved a larger group of patients than our PMA filing and included one-year follow up. These results showed that at 12 months after implant, 80 percent of patients had undergone heart transplantation, recovered heart function and had the device removed, or were continuing on device support. Other data demonstrated the effectiveness of the device in larger patients, showed improvements in cognitive function during LVAD support, and showed improved functional status of patients compared to cardiac resynchronization therapy (CRT) in Class IV patients. There were also encouraging data demonstrating the value of predictive models that can aid in patient selection and management programs, which is supportive of our market development efforts," he concluded. The company also updated enrollment in its Pivotal clinical trial for the HeartMate II. As of April 25, 2008, there were 532 patients enrolled in the Destination Therapy (DT) arm of the trial. Enrollment in the randomized portion of the DT arm of the trial was 325 patients. Enrollment in the BTT arm of the trial was 486 patients at the time of the approval. FINANCIAL HIGHLIGHTS Thoratec reported revenues of $64.4 million in the first quarter of 2008 compared with revenues of $57.3 million in the first quarter of 2007. Cardiovascular Division revenues were $40.2 million versus $35.5 million in the same period a year ago. Revenues at ITC were $24.2 million versus $21.8 million a year ago. GAAP gross margin for the first quarter of 2008 was 55.6 percent versus 60.2 percent a year ago. Non-GAAP gross margin, which excludes SFAS No. 123R expense and is described later in this press release, was 56.3 percent versus 60.8 percent a year ago. The year-over-year decrease in gross margin is primarily attributed to fluctuations in capitalized manufacturing variances and unfavorable pump to non-pump product mix in the Cardiovascular Division and geographic mix at ITC, offset by favorable foreign exchange rates. Operating expenses for the first quarters of 2008 and 2007 on a GAAP basis were $36.5 million and $36.0 million, respectively. On a non-GAAP basis, operating expenses in the first quarter of 2008 were $30.7 million compared with $29.7 million in the first quarter of 2007. Operating expenses on a non-GAAP basis are described later in this press release. The year-over-year increase in operating expenses is primarily due to product development expense and market development initiatives. The company's GAAP effective tax rate for the first quarter of 2008 was 48 percent versus a benefit of 23 percent in the first quarter of 2007. The non-GAAP tax rate for the first quarter of 2008, which is described later in this press release, was 34 percent versus 31 percent in the prior year. The increase in tax rates was primarily attributed to the absence of R&D tax credits in 2008, which will be recognized in a future period if approved by Congress, along with foreign tax true-ups. On a non-GAAP basis the company's convertible debt was dilutive to the company's fully diluted weighted average shares outstanding. The increase in shares was approximately 7.3 million. Cash and investments at the end of the quarter were $221 million, including $32 million of Auction Rate Securities classified as long term investments. Management affirmed its previously issued guidance for 2008. CONFERENCE CALL/WEBCAST INFORMATION
GAAP TO NON-GAAP RECONCILIATION Thoratec management evaluates and makes operating decisions using various measures. These measures are generally based on revenues generated by its products and certain costs of producing that revenue, such as costs of product sales, research and development and selling, general and administrative expenses. We use the following measures, which are not calculated in accordance with Generally Accepted Accounting Principles ("GAAP"): non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP tax rate, non-GAAP net income, and non-GAAP EPS. These are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. These non-GAAP financial measures are calculated by excluding certain GAAP financial items that we believe have less significance to the day-to-day operation of our business. The company has outlined below the type and scope of these exclusions and the limitations on the use of the non-GAAP financial measures as a result of these exclusions. Management uses these non-GAAP financial measures for financial and operational decision making, including in the determination of employee annual cash incentive compensation, as a means to evaluate period-to-period comparisons, as well as comparisons to our competitors' operating results. Management also uses this information internally for forecasting and budgeting, as it believes that the measures are indicative of Thoratec core operating results. Management also believes that non-GAAP financial measures provide useful supplemental information to management and investors regarding the performance of the company's business operations, provide a greater transparency with respect to key metrics used by management in its decision making, facilitate comparisons of results for current periods and guidance for future periods with our historical operating results, and assist in analyzing future trends. Non-GAAP net income (loss) consists of GAAP net income (loss) before taxes, excluding, as applicable, share-based compensation expense under SFAS No. 123R, amortization of purchased intangibles, changes in the value of the 2007 make-whole provision of our convertible notes, as adjusted by the amount of additional taxes payable or tax benefit that the company would accrue if it used non-GAAP results instead of GAAP results to calculate the company's tax liability. Non-GAAP EPS is defined as non-GAAP net income divided by the weighted average number of shares on a fully-diluted basis. Non-GAAP gross profit and gross margin consists of GAAP gross profit and gross margin excluding share-based compensation expense under SFAS No 123R. Non-GAAP operating expenses consists of GAAP operating expenses excluding share-based compensation expense under SFAS No. 123R and amortization of purchased intangibles. Non-GAAP income from operations consists of GAAP income from operations excluding share-based compensation expense under SFAS No. 123R and amortization of purchased intangibles. Non-GAAP tax rate consists of the GAAP tax rate adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income. Management believes that it is useful in measuring Thoratec's operations to exclude amortization of intangibles, and in-process research and development expenses. These costs are primarily fixed at the time of an acquisition and, unlike other fixed costs that result from ordinary operations, are the result of infrequent and irregular events. Management believes it is useful to exclude the value of the 2007 make-whole provision of our convertible notes as this item is also not indicative of Thoratec's core operating business. The make-whole provision is a non-operating item that is included in other income (expense) and is part of our financing activities in 2007. Because of varying valuation methodologies, subjective assumptions and the variety of award types that companies can use under SFAS No. 123R, Thoratec management believes that providing non-GAAP financial measures that exclude share-based compensation allows investors to compare Thoratec's recurring core business operating results to those of other companies and over multiple periods. The exclusion also enhances investors' ability to review Thoratec's business from the same perspective as Thoratec management, which believes that share-based compensation expense is not directly attributable to the underlying performance of the company's business operations. There are a number of limitations related to the use of non-GAAP financial measures. First, non-GAAP financial measures exclude some costs, namely share-based compensation, that are recurring expenses. Second, share-based compensation is part of an employee's compensation package and as such may be useful for investors to consider. Third, the components of costs that we exclude in our non-GAAP financial measures calculations may differ from components that our peer companies exclude when they report their results from operations. Non-GAAP financial measures should not be considered as a substitute for measures of financial performance in accordance with GAAP. However, these measures may provide additional insight into Thoratec's financial results. Investors and potential investors are strongly encouraged to review the reconciliation of non-GAAP financial measures contained within this press release with their most directly comparable GAAP financial results and not to rely on any single financial measure to evaluate our business. The reconciliations of the forward looking non-GAAP financial measures to the most directly comparable GAAP financial measures in tables below include all information reasonably available to Thoratec at the date of this press release. These tables include adjustments that we can reasonably predict. Events that could cause the reconciliation to change include acquisitions and divestitures of business, goodwill and other asset impairments and sales of marketable equity securities. The following table includes the GAAP income statement for the three month periods ending in 2008 and 2007. THORATEC CORPORATION
Net income (loss) per share Shares used to compute net income per share: The following table reconciles the specific items excluded from GAAP net income in the calculation of non-GAAP net income for the periods shown below: THORATEC CORPORATION Three Months Ended
Diluted net income (loss) per share (in thousands, except per share data) (A) The company's total diluted share count on a non-GAAP basis in Q1 2008 (B) The Make-whole provision is included in Non-GAAP earnings for Q1 2008. The following table reconciles the specific items excluded from GAAP gross profit and gross margin in the calculation of non-GAAP gross profit and gross margin for the periods shown below: THORATEC CORPORATION Three Months Ended Gross profit on a GAAP basis $35,837 55.6% $34,513 60.2% The following tables reconcile the specific items excluded from GAAP operating expenses in the calculation of non-GAAP operating expenses for the periods shown below: THORATEC CORPORATION
Operating expenses on a GAAP basis $36,451 $35,991 The following table reconciles the GAAP tax rate adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income. THORATEC CORPORATION
Tax benefit (expense) on a GAAP basis $(325) 48.2% $84 23.4%
Many of the preceding paragraphs, particularly but not exclusively those addressing guidance for fiscal 2008 financial results, future performance or timelines and milestones for clinical trials, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "projects," "hopes," "could," "will," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to the development of new markets including Destination Therapy, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, changes in the mix of existing markets for our products and related gross margin for such product sales, the results of enrollment in and timing of clinical trials, including for the HeartMate II, the ability to improve financial performance, regulatory approval processes, the effects of healthcare reimbursement and coverage policies, the effects of seasonality in Thoratec product sales, the effects of price competition from any Thoratec competitors and the effects of any merger and acquisition related activities. Forward-looking statements contained in this press release should be considered in light of these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K, and as may be updated in subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Thoratec undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events. First Call Analyst:
CONTACT: David Smith, Executive Vice President, Chief Financial Officer, Web site: http://www.thoratec.com/
Multi-Organ Transplant Program - UAMS Multi-Organ Transplant Program
Multi-Organ Transplant Program . A generation ago, a patient with a failing heart, kidneys, pancreas or liver had little chance of survival. Fortunately, today that has all changed [full story]
BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
BIRMINGHAM, Ala., May 1 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (NASDAQ:BCRX) today announced that its first quarter 2008 financial results will be released on Thursday, May 8, 2008. At 8:30 a.m. Eastern Time BioCryst will host a conference call and webcast to discuss the financial results and provide an update on the Company's programs and further clinical data. The call will be led by Jon P. Stonehouse, BioCryst's Chief Executive Officer, and Stuart Grant, BioCryst's Chief Financial Officer. The webcast can be accessed by logging onto http://www.biocryst.com/. Please connect to the website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. To participate in the conference call, please dial 1-800-860- 2442 (U.S.). The audio portion of the webcast will be archived and available for replay for 14 days. About BioCryst BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The Company is advancing multiple internal programs toward potential commercialization including forodesine HCl in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life-threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization of BCX-4208, and is collaborating with Mundipharma for the development and commercialization of forodesine HCl in markets across Europe, Asia, Australia and certain neighboring countries. In January 2007, the U.S. Department of Health and Human Services (HHS) awarded a $102.6 million, four-year contract to BioCryst to advance development of peramivir to treat seasonal and life-threatening influenza. In February 2007, BioCryst established a partnership with Shionogi & Co. to develop and commercialize peramivir in Japan. For more information about BioCryst, please visit the Company's web site at http://www.biocryst.com/ . Forward-looking statements This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase II clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that the Phase II trial of BCX-4208 for psoriasis may not be successfully completed, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates, that our projected burn rate may not be consistent with our expectations, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (File No. 333-145638), Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements. Contact: Stuart Grant, CFO of BioCryst Pharmaceuticals (205) 444-4600 First Call Analyst:
CONTACT: Stuart Grant, CFO of BioCryst Pharmaceuticals, +1-205-444-4600 Web site:
Controversial new organ donor register (TVNZ)
Controversial new organ donor register (TVNZ)
A controversial new organ donor register has been launched which promises preferential treatment for anyone signing up. But doctors say it is not legally binding and is morally repugnant. Kidney Transplant - UK HealthCare
The UK Transplant Center has been providing transplantation services since 1964. Our surgeons now perform over 130 transplants each year. The faculty and staff of the Transplant [continued]
Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10%
Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10%
EATONTOWN, N.J., May 1 /PRNewswire-FirstCall/ -- Osteotech, Inc. (NASDAQ:OSTE), a leader in the emerging field of biological products for regenerative healing, announced today that revenue for the first quarter of 2008 increased 10% to $27.6 million from $25.2 million for the first quarter of 2007. Revenue from the Company's primary product lines, included in the DBM and Hybrid/Synthetic segments, was $17.6 million for the three months ended March 31, 2008, an increase of 12% over the prior year period. Revenue from our other product lines was $10.0 million and $9.5 million in the first quarter of 2008 and 2007, respectively. Diluted earnings per share for the quarter ended March 31, 2008 was $.05 on net income of $.8 million compared to a net loss of $.6 million, or $.04 diluted loss per share, for the first quarter of 2007. The net loss in the first quarter of 2007 included the costs associated with the settlement of certain litigation and related legal fees of $1.1 million. Gross margin improved to 52% in the first quarter compared to 49% in the first quarter of the prior year. Operating expenses increased 5% for the three months ended March 31, 2008 compared to the same period in 2007 due primarily to increased spending in research and development activities. Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "We continue to be pleased with the execution of our strategic initiatives. During the first quarter, we have continued to expand our product pipeline, penetrate the foot and ankle market with our Plexur P(TM) product and improve the effectiveness of our sales force. In the past two months, we have received FDA clearance for our Plexur P(TM) product for use in the spine and the Plexur M(TM) for use in orthopedics; renewed our tissue recovery agreement with the Euro Atlantic Transplant Alliance; entered into an agreement to distribute the Harvest(TM) Technologies BMAC(TM) System; and engaged BioHorizons to distribute our bone regeneration products in the international dental market. We are very excited about our future." Mr. Owusu-Akyaw will host a conference call on May 1, 2008 at 9:00 a.m. Eastern Time to discuss first quarter results. You are invited to listen to the conference call by dialing 706-643-1624. The conference will also be simultaneously webcast at http://www.osteotech.com/. Automated playback will be available two hours after completion of the live call, through midnight, Thursday, May 15th, by dialing 706-645-9291 and indicating access code 43861543. Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, this press release or the conference call, please go to Osteotech's website at www.osteotech.com. Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. Certain of these factors are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of May 1, 2008 and the Company does not intend to update this information. OSTEOTECH, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Revenue $ 27,631 $ 25,217 Cost of revenue 13,389 12,900 Gross profit 14,242 12,317 Marketing, selling and general and Operating income (loss) 802 (537) Interest expense, net (212) (150) Income (loss) before income taxes 868 (551) Earnings (loss) per share: Shares used in computing earnings (loss) CONSOLIDATED SEGMENT REVENUE DETAIL Three Months DBM $16,966 $15,482 Revenue $27,631 $25,217 OSTEOTECH, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS March 31, December 31, Liabilities and Stockholders' Equity
CONTACT: Mark H. Burroughs of Osteotech, Inc., +1-732-542-2800 Web site: Company News On-Call: http://www.prnewswire.com/comp/668050.html
Novadaq to hold first quarter 2008 results conference call and webcast
Novadaq to hold first quarter 2008 results conference call and webcast
TORONTO, May 1 /PRNewswire-FirstCall/ -- Novadaq(R) Technologies Inc. (TSX: NDQ), a developer of real-time medical imaging and image guidance systems for the operating room, will host a conference call and live webcast on Monday, May 12, 2008 at 10:00 a.m. E.T. to discuss the financial results for the first quarter ended March 31, 2008. To access the conference call by telephone, dial 416-644-3422 or 1-800-731-5319. Please connect approximately ten minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until May 19, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21270216 followed by the number sign. A live audio webcast of the conference call will be available at www.novadaq.com. Please connect at least ten minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 365 days. About Novadaq Technologies Novadaq Technologies Inc. commercializes real-time imaging and image guidance systems for use in the operating room. With one set of proprietary core technologies, Novadaq's products have multiple applications. Novadaq's SPY(R) System enables cardiac surgeons to diagnose intra-operatively by visually assessing coronary vasculature and bypass graft functionality during the course of heart bypass surgery. The SPY System is also indicated for use during other surgeries, such as cardiovascular, plastic, reconstructive, organ transplant and urological procedures. SPY can be used to visualize blood vessels, tumors, tumor margins and the lymphatic system. Novadaq introduced PINPOINT(TM), its first minimally invasive imaging system for autofluorescence in October 2007. PINPOINT allows surgeons to differentiate between healthy and cancerous tissue in the lung and other hollow organs. Further expanding its portfolio of minimally invasive products, Novadaq is developing SPYscope which combines the typical features of a standard endoscope with the additional capabilities of SPY imaging. Novadaq is the exclusive United States distributor of PLC Medical's CO2 HEART LASER System, used in the same cardiac procedures as the SPY System. Novadaq also offers the OPTTX(R) System, which leverages the company's core imaging technology and is designed for the diagnosis, evaluation and treatment of wet Age-related Macular Degeneration (AMD). For more information, please visit the company's website at www.novadaq.com. Forward looking Statements Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Novadaq's current beliefs as well as assumptions made by and information currently available to Novadaq and relate to, among other things, results of future clinical tests of PINPOINT and the SPY System, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: For further information visit our website at www.novadaq.com, or
Cautious welcome for Philippines transplant ban (AFP via Yahoo! News)
Cautious welcome for Philippines transplant ban (AFP via Yahoo! News)
Church leaders and human rights campaigners Wednesday welcomed a ban by the Philippines on organ transplants to foreigners but cautioned that loopholes may still allow kidney trafficking to persist. ArchivesMar 21, 2008 Mar 22, 2008 Mar 23, 2008 Mar 24, 2008 Mar 25, 2008 Mar 26, 2008 Mar 27, 2008 Mar 28, 2008 Mar 29, 2008 Mar 30, 2008 Mar 31, 2008 Apr 1, 2008 Apr 2, 2008 Apr 3, 2008 Apr 4, 2008 Apr 5, 2008 Apr 6, 2008 Apr 7, 2008 Apr 8, 2008 Apr 9, 2008 Apr 10, 2008 Apr 11, 2008 Apr 12, 2008 Apr 13, 2008 Apr 14, 2008 Apr 15, 2008 Apr 16, 2008 Apr 17, 2008 Apr 18, 2008 Apr 19, 2008 Apr 20, 2008 Apr 21, 2008 Apr 22, 2008 Apr 23, 2008 Apr 24, 2008 Apr 25, 2008 Apr 26, 2008 Apr 27, 2008 Apr 28, 2008 Apr 29, 2008 Apr 30, 2008 May 1, 2008 Subscribe to Posts [Atom] |
|
| |||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||
